The cost‐effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain

BACKGROUND: Invasive mould diseases are associated with high morbidity, mortality and economic impact. Its treatment is often started prior to differential pathogen diagnosis. Isavuconazole is approved for treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) when amphotericin‐B is...

Descripción completa

Detalles Bibliográficos
Autores principales: Azanza, José Ramón, Grau, Santiago, Vázquez, Lourdes, Rebollo, Pablo, Peral, Carmen, López‐Ibáñez de Aldecoa, Alejandra, López‐Gómez, Vanessa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894146/
https://www.ncbi.nlm.nih.gov/pubmed/32989796
http://dx.doi.org/10.1111/myc.13189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894146/
https://www.ncbi.nlm.nih.gov/pubmed/32989796
http://dx.doi.org/10.1111/myc.13189

Ejemplares similares